NVCT
Nuvectis Pharma, Inc. Common Stock [NVCT] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NVCT Stock Summary
In the News
NVCT Financial details
Company Rating
-
Market Cap
124.74M
Income
-22.21M
Revenue
4.1M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
13
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-7.43
Forward P/E
-
PEG
13.75
P/S
41.54
P/B
9.84
P/C
-
P/FCF
-11.3
Quick Ratio
3.96
Current Ratio
3.99
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.4
EPS next Y
-
EPS next Q
-
EPS this Y
-3.38%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
2.7%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-33.33%
Inst Own
-
Inst Trans
-
ROA
-99%
ROE
-139%
ROC
-1.37%
Gross Margin
-181%
Oper. Margin
-537%
Profit Margin
-520%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6.2-18.65
52W High
-62.83%
52W Low
+11.5%
RSI
59
Rel Volume
2.71
Avg Volume
106.45K
Volume
288.14K
Perf Week
11.13%
Perf Month
4.53%
Perf Quarter
-25.58%
Perf Half Y
-37.18%
-
-
-
-
Beta
0.27
-
-
Volatility
0.26%, 0.19%
Prev Close
4.04%
Price
6.69
Change
1.21%
Company Profile
- Volume Average 106.45K
- Market Capitalization 124.74M
- Employee 13
- CEO Mr. Ron Bentsur M.B.A.
- Headquarters Fort Lee,NJ,US
- IPO Date 2022-02-04
-
Website
https://www.nuvectis.com 
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
